Bio­gen piv­ots to sec­ond amy­loid-tar­get­ed Alzheimer's drug with ac­cel­er­at­ed ap­proval fil­ing from part­ner Ei­sai

Al­most ex­act­ly a year ago, Bio­gen CEO Michel Vounatsos boast­ed that the com­pa­ny’s new Alzheimer’s drug, prep­ping for bil­lions in sales fol­low­ing its quick FDA ap­proval, was a “first-in-class med­i­cine” that “will trans­form the treat­ment of peo­ple liv­ing with Alzheimer’s dis­ease.”

One year lat­er and Aduhelm has been used in very few pa­tients, Ei­sai has ba­si­cal­ly dropped its in­volve­ment, and now the drug has been all but com­plete­ly dis­card­ed by Bio­gen as the com­pa­ny is un­der at least a half dozen in­ves­ti­ga­tions from the FDA, HHS, SEC, FTC and con­gres­sion­al com­mit­tees re­lat­ed to its close links with the FDA and how it won ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER